Dr. Suliman has served as a member of the Ultragenyx Board since January 2019. She most recently served as President and Chief Operating Officer of Alector, Inc. Prior to Alector, she was Senior Vice President, Corporate Development and Strategy, for Theravance Biopharma, Inc. Prior to her position at Theravance, Dr. Suliman worked for Genentech, Inc. as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group from September 2010 to May 2015 and then as Vice President and Global Therapeutic Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc. between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners, advising public and private companies on buy- and sell-side transactions. She is a member of the Board of Directors of 10X Genomics, Inc., as well as Parvus Therapeutics, Inc., a private biopharmaceutical company. Dr. Suliman received an M.D. from the University of Cape Town Medical School, South Africa, and an M.B.A, with distinction, and an M.Phil. in development studies from Oxford University, where she was a Rhodes Scholar.